β受体阻滞剂在慢阻肺合并心血管疾病中的真实世界死亡率效应
基于英国CPRD Aurum数据库的队列研究,采用模拟试验的现患新用户设计,匹配11594例β受体阻滞剂起始者与11594例非使用者。结果显示β受体阻滞剂与全因死亡率降低相关(HR 0.88,95%CI 0.81-0.95),但该效应仅限于心衰或缺血性心脏病患者,且合并使用长效β2激动剂可能削弱其获益。
要点
- 慢阻肺合并心血管疾病患者使用β受体阻滞剂与全因死亡率降低相关(HR 0.88)。
- 获益主要见于心衰(HR 0.77)和缺血性心脏病(HR 0.84)患者。
核心结论
- β受体阻滞剂可降低慢阻肺合并心血管疾病患者的全因死亡率,但仅限心衰或缺血性心脏病患者,房颤或高血压患者未见获益。
- 合并使用长效β2激动剂可能削弱β受体阻滞剂的死亡率获益。
研究设计与样本
- 基于英国CPRD Aurum数据库的队列研究,纳入2002年1月至2021年3月年龄≥40岁的慢阻肺合并心血管疾病患者。
- 采用现患新用户设计模拟试验,按时间、倾向评分及心血管适应症匹配β受体阻滞剂起始者与非使用者。
- 共纳入11594例β受体阻滞剂起始者和11594例匹配非使用者,采用as-treated方法估计全因死亡风险比。
主要发现
- β受体阻滞剂使用相对于非使用的全因死亡HR为0.88(95%CI 0.81-0.95)。
- 心衰患者HR为0.77(95%CI 0.66-0.89),缺血性心脏病HR为0.84(95%CI 0.73-0.98)。
- 房颤患者HR为0.96(95%CI 0.83-1.11),高血压患者HR为1.10(95%CI 0.87-1.38)。
临床怎么用
- 对慢阻肺合并心衰或缺血性心脏病的患者,可考虑启用β受体阻滞剂以降低死亡风险。
- 合并使用长效β2激动剂时需权衡β受体阻滞剂的预期获益可能减弱。
- 房颤或高血压的慢阻肺患者使用β受体阻滞剂未见死亡率获益,决策应基于其他适应症。
局限性
- 观察性设计模拟试验仍可能存在残余混杂。
- 结果基于英国数据库人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although beta-blockers are effective at reducing mortality in certain cardiovascular diseases (CVDs), their effectiveness in patients with COPD and CVD is uncertain, particularly with the concurrent use of long-acting beta2-agonists (LABAs). RESEARCH QUESTION: Is the initiation of beta-blockers in patients with COPD and CVD associated with reduced mortality, and is this effect influenced by concurrent use of LABAs? STUDY DESIGN AND METHODS: The United Kingdom's Clinical Practice Research Datalink (CPRD) Aurum network was used to form a cohort of patients with COPD and CVD from January 2002 to March 2021 who were aged ≥ 40 years. A prevalent new-user design, conceived to emulate a trial, was used, matching initiators of beta-blockers with nonusers on time and propensity score as well as CVD indication, namely heart failure (HF), ischemic heart disease (IHD), atrial fibrillation, and hypertension. Hazard ratios (HRs) and 95% CIs of all-cause mortality were estimated by using an as-treated approach. RESULTS: The study cohort included 11,594 initiators of beta-blockers and 11,594 matched nonusers. The HR of death with beta-blocker use relative to nonuse was 0.88 (95% CI, 0.81-0.95). The HR was 0.95 (95% CI, 0.85-1.05) among concurrent LABA users and 0.80 (95% CI, 0.71-0.91) among LABA nonusers (Pinteraction = .04), an effect driven by patients with IHD (Pinteraction = .01). The HR was 0.77 (95% CI, 0.66-0.89) among patients with HF, 0.84 (95% CI, 0.73-0.98) for IHD, 0.96 (95% CI, 0.83-1.11) for atrial fibrillation, and 1.10 (95% CI, 0.87-1.38) for hypertension. INTERPRETATION: This large population-based study, designed to emulate a trial, suggests that beta-blocker use is effective at reducing all-cause mortality in patients with COPD and CVD but only in those with HF or IHD, not in those with atrial fibrillation or hypertension. The concurrent use of LABAs could mitigate the effectiveness of beta-blockers at reducing mortality.
引用
- Suissa S, Dell'Aniello S, Renoux C, et al. Effectiveness of Beta-Blockers in COPD and Cardiovascular Disease: Real-World Effects on Mortality. Chest. 2026. PMID: 42580516. doi:10.1016/j.chest.2026.06.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。